The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    AV007
Previous Study | Return to List | Next Study

Actovegin® Versus Placebo in Patients With Diabetic Polyneuropathy (AV-007-IM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00483730
Recruitment Status : Completed
First Posted : June 7, 2007
Last Update Posted : May 7, 2012
Sponsor:
Information provided by:
Nycomed

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
To assess clinical efficacy and safety of Actovegin in type 2 diabetic patients with symptomatic diabetic peripheral polyneuropathy after 250 ml i.v. infusions once daily for 20 days followed by oral treatment 600 mg × 3 daily for 140 days.

Condition or disease Intervention/treatment Phase
Symptomatic Diabetic Peripheral Polyneuropathy Drug: Deproteinised hemoderivative of calf blood (Actovegin) Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 569 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multi-centre, Double-blind, Placebo-controlled, Randomised, Parallel Group Clinical Trial to Evaluate Efficacy and Safety of Actovegin® in Diabetic Type 2 Patients With Symptomatic Diabetic Peripheral Polyneuropathy
Study Start Date : December 2006
Actual Primary Completion Date : May 2008
Actual Study Completion Date : December 2008
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Intervention Details:
  • Drug: Deproteinised hemoderivative of calf blood (Actovegin)
    Symptomatic diabetic peripheral polyneuropathy

Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. TSSaverage: Average of the TSS over the treatment period (AUC / exposure time) VPTaverage: Average of the VPT measurement over the treatment period (AUC / exposure time) [ Time Frame: Approx. 5½ months ]

Secondary Outcome Measures :
  1. NIS-LLaverage: Average of the NIS-LL over the treatment period (AUC / exposure time) [ Time Frame: Approx. 5½ months ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

The medical condition / disease to be studied is symptomatic diabetic peripheral polyneuropathy.

All inclusion criteria must be answered "yes" for a patient to participate in the trial.

  1. Has the patient given informed consent according to local requirements before any trial related activities? A trial related activity is any procedure that would not have been performed during the routine management of the patient.
  2. Is the patient aged ≥ 18 to ≤ 65 years?
  3. Does the patient suffer from type 2 diabetes mellitus?
  4. Has the patient evidence of symptomatic diabetic peripheral polyneuropathy, i.e. TSS ≥ 6 and NIS-LL ≥ 2?
  5. Is the patient's VPT measured to ≤ 30V?
  6. Has the patient adequate circulation to the foot as evidenced by a palpable pulse on posterior tibialis artery and dorsal artery of foot?
  7. Is the HbA1C level less than 10%?

  8. Is the patient able to make frequent clinic visits over the trial period?

    For patients receiving tricyclic antidepressants, anticonvulsants, mexiletine or neuroleptics as treatment of neuropathic pain:

  9. Has the regimen been stable within the last month?

    For female patients of childbearing potential (childbearing potential is considered until menopause has lasted more than 12 months):

  10. Does the patient use an acceptable contraceptive method (hormonal pills, patches, implants, injections or intrauterine device)?
  11. Is the pregnancy test negative before the 1st dose of trial medication?

(Surgically hysterectomised and surgically successfully sterilized females may be included on the same conditions as male patients).

Exclusion Criteria:

All exclusion criteria must be answered "no" for a patient to participate in the trial.

  1. Does the patient suffer from known allergy towards Actovegin or similar preparations?
  2. Has the patient asymmetrical neuropathy of the trunk or proximal lower limbs?
  3. Does the patient suffer from diabetic foot ulceration or infections?
  4. Does the patient suffer from diabetic amyotrophy?
  5. Does the patient suffer from decompensated cardiac insufficiency, pulmonary oedema, oliguria, anuria, generalised oedema?
  6. Does the patient suffer from polyneuropathy due to other underlying causes?
  7. Has the patient been hospitalised due to diabetic polyneuropathy within the last month?
  8. Has the patient participated in any other trial with an Investigational Medicinal Product (IMP) or device within 30 days before inclusion in this trial?
  9. Has the patient ever used medications that may be etiological factors for neuropathy, such as isoniazid, nitrofurantoin, vincristine and phenytoin?
  10. Has the patient used cerebrolysin or α-lipoic acid or received Transcutaneous Electric Nerve Stimulation (TENS) or acupuncture within the last month?
  11. Has the patient received opiates as treatment of his / her diabetic polyneuropathy within the last month?
  12. Does the patient suffer from any malignancy?
  13. Is the patient nursing?
  14. Does the patient suffer from any mental, psychiatric or other conditions that may compromise data collection and understanding of written and verbal information given in the trial?
  15. Does the patient suffer from present and / or previous chronic alcohol abuse?
  16. Is there any anamnestic evidence of hypothyroidism?
  17. Is there any anamnestic evidence of vitamin B12 deficiency?
  18. Does the patient suffer from an impaired renal function with high blood urea nitrogen (BUN) and / or increased serum creatinine (>120 µmol/L)?
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00483730


Locations
Layout table for location information
Denmark
Nycomed
Roskilde, Denmark, 4000
Sponsors and Collaborators
Nycomed
Investigators
Layout table for investigator information
Study Chair: Nycomced Clinical Trial Operations Headquaters
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Nycomed
ClinicalTrials.gov Identifier: NCT00483730    
Other Study ID Numbers: AV-007-IM
First Posted: June 7, 2007    Key Record Dates
Last Update Posted: May 7, 2012
Last Verified: May 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Polyneuropathies
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Actovegin
Central Nervous System Stimulants
Physiological Effects of Drugs
 Anti-Ulcer Agents
Gastrointestinal Agents
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Radiation-Protective Agents